NCT02110225View on ClinicalTrials.gov

A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Retinitis Pigmentosa
Interventions
DRUG

rhNGF 60 µg/ml eye drops solution

rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes

DRUG

rhNGF 180 µg/ml eye drops solution

rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes

DRUG

Placebo

Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes

Trial Locations (5)

20142

Azienda Ospedaliera San Paolo - U.O. Oculistica, Milan

50124

Azienda Ospedaliero Universitaria Careggi, Florence

80129

A.O. Seconda Università Degli Studi di Napoli - Nuovo Policlinico - UOC Oftalmologia, Naples

00168

Università Cattolica del Sacro Cuore - Policlinico Gemelli - Istituto di Oftalmologia, Rome

00198

IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia, Rome

All Listed Sponsors
lead

Dompé Farmaceutici S.p.A

INDUSTRY

NCT02110225 - A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP) | Biotech Hunter | Biotech Hunter